Targeted Therapy for Non-Small Cell Lung Cancer Using Antibody-Coated Gold Nanoparticles
| dc.creator | Koneru, Bhuvaneswari | |
| dc.creator | Shi, Yi | |
| dc.creator | Moron, Sebastian | |
| dc.creator | Di Pasqua, Anthony | |
| dc.date.accessioned | 2019-08-22T19:35:59Z | |
| dc.date.available | 2019-08-22T19:35:59Z | |
| dc.date.issued | 2015-03 | |
| dc.date.submitted | 2015-03-04T07:41:54-08:00 | |
| dc.description.abstract | Purpose:Lung cancer is the leading cause of cancer-related death in the United States among both men and women. Approximately 85 to 90% of all lung cancers are non-small cell lung cancer (NSCLC). Unfortunately, NSCLC is extremely difficult to treat and survival rates are low (the five year survival rate is Methods: AuNPs with pendant –COOH and –OH groups are synthesized by the reduction of gold ions in the presence of a mixture of alkanethiols. A targeting ligand (mAb) is attached to the AuNPs by EDC-coupling. The size and zeta potential of the AuNPs is determined using dynamic light scattering and TEM, and the amount of antibody conjugation quantified via colorimetry. Uptake of AuNP and AuNP-mAb in various NSCLC cell lines with various levels of expression of the adhesion molecule was then performed Results: AuNP-mAb was synthesized, characterized and uptake tested in cell culture. We anticipate next to attach a platinum prodrug and test for use in targeted therapy for NSCLC. | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12503/26371 | |
| dc.language.iso | en | |
| dc.title | Targeted Therapy for Non-Small Cell Lung Cancer Using Antibody-Coated Gold Nanoparticles | |
| dc.type | poster | |
| dc.type.material | text |